The cannabis industry revolution
The global cannabis industry is about to enter its third phase, and unlike previous stages, this current one is the most challenging and important step yet.
Over the past 3 years, more and more scientific and clinical data have been collected and published. Many health benefits which were known to Cannabis users only, became accessible to the public, with many countries legalizing cannabis, notably Canada. In addition, health authorities and agencies such as WHO, IMOH, TGA, FDA, and others are creating the regulatory framework which will enable a controlled and organized methodology, enabling people to receive safe and high-quality cannabis products.
The importance of Cannabis consultancy
The global cannabis industry is making its first steps towards “Medicalization”. This means that just like other pharmaceuticals and medical supplements being sold to people, it should meet strict regulatory requirements. These requirements ensure that cannabis products are safe for consumption, meet the strength, purity and identity characteristics and is the absolute best quality.
In most of the countries that legalize medical cannabis usage, the health ministry and authorities are in charge of writing the regulations as well as to inspect cannabis growers and manufacturers. These agencies usually work with medical and pharmaceutical companies and as such, their expectations are relatively high.
In the past, the cannabis industry has never had to face pharmaceutical standards such as GAP (Good Agriculture Practices), GMP (Good Manufacturing Practices) and GDP (Good Distribution Practices).
In order to meet the challenges, the required resources have to be available. You need to hire the right consultancy firms who have vast and combined experience from both the pharmaceutical and the Cannabis industries. On one hand, implementation of pharmaceutical standards in the cannabis industry will ‘kill’ this industry, and on the other hand, implementation of agriculture, food and supplements standards will not be sufficient and will lead to regulatory compliance failures.
The global cannabis industry will need to find the right partners in cannabis consulting firms which have the required regulatory capabilities as well as a proven track record.
Cannabis GXP consultancy approach
Cannabis GXP began it’s journey 12 years ago. Based on our multidisciplinary experience in the pharmaceutical, medical and cannabis industry, from Israel and internationally, we are in the process of revolutionizing the world of cannabis and Hemp regulation and are reaching out to companies and growers who want to join this amazing ride with us.
For the time being, the global Cannabis industry is unregulated, mainly due to the illegality of these substances throughout the years, BUT things are changing rapidly and nobody wants to be left behind. That’s why we are proud to be at the forefront of the GAP, GMP and GDP standards and regulation fields in Israel.
The team at Cannabis GXP is compelled to spread the message of the importance of Cannabis regulation and standardization, as the world enters a new era. In this way, we hope that our clients will be positioned in the best way possible, with their best foot forward when it comes to anything and everything Cannabis related.
Cannabis GXP is a leading consultancy firm, working within the Cannabis industry, overseeing the production of new cannabis products and extracts.
We also assist new companies and growers with new facility design, Quality Assurance, Good Practices (GAP/GMP/GDP), training and a strong emphasis on regulation in different countries.
Cannabis GXP is a subsidiary company of Bio-Chem Ltd. (2007) – a consultancy company for Pharmaceutical, Medical Devices, Cosmetics, and Supplements, based in Israel (http://bio-chem.co.il/en/home/)
Cannabis GXP consulting services
Cannabis GXP is focused on enabling our customers to develop, manufacture and distribute high-quality pharma grade Cannabis-based products, with an emphasis on safety, efficacy, and professionalism.
Among some of our bigger clients are Teva, Tikun Olam (the largest Medical Cannabis company in Israel.) J&J, Weizmann Institute of Science, BOL pharma, Seach, Nuuvera, Gamma-Cert, Cannabillis, Monsanto, Evogene, Collplant, Sigma-Aldrich and many others.
Our cannabis consultancy services include:
- Investigational Cannabis product development and clinical trials
- Cannabis growing & manufacturing facilities design
- Cannabis Quality Assurance & Good practices (GxP)
- Cannabis product manufacturing technology
- Cannabis product regulation & FDA/EU submission
- Novel Cannabis APIs and product delivery systems
About Cannabis GxP consultancy
Cannabis GXP is proud to stand at the forefront of the Cannabis industry in Israel and worldwide thanks to many years of experience in these areas.
Our team is compelled to spread the message of the importance of cannabis science, regulation and standardization as the world enters a new era of cannabis legislation.
We aim to position our clients with their best foot forward when it comes to anything and everything cannabis related.
Our vast expertise allows us to assist companies in a wide range of services and needs: Anything from Cannabis R&D, growing and manufacturing, new products development, facility design, technology, Quality Assurance, Good Practices (GAP/GMP/GLP/GDP/GCP), staff training, local and global regulations.
Cannabis GxP is a subsidiary company of Bio-Chem Ltd. (2007), a consultancy firm for the Pharmaceutical field, Medical devices, Cosmetics and food supplements industry based in Israel.
Our cannabis consultancy services include:
- Product development, delivery system & clinical trials
- Growing, Manufacturing and Lab Facilities Design
- Quality Assurance and Good Practices (GxP)
- Cultivation & Product Manufacturing Technology
- New product Regulations and Submissions
- Qualification & Validation
- Risk Assessment
- Staff training
If you need consultancy or one or several of our services, we will be more than happy to assist.
Please do not hesitate to contact us for further information.